JPWO2020203950A1 - - Google Patents

Info

Publication number
JPWO2020203950A1
JPWO2020203950A1 JP2021512102A JP2021512102A JPWO2020203950A1 JP WO2020203950 A1 JPWO2020203950 A1 JP WO2020203950A1 JP 2021512102 A JP2021512102 A JP 2021512102A JP 2021512102 A JP2021512102 A JP 2021512102A JP WO2020203950 A1 JPWO2020203950 A1 JP WO2020203950A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021512102A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2020203950A1 publication Critical patent/JPWO2020203950A1/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53861,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021512102A 2019-03-29 2020-03-30 Pending JPWO2020203950A1 (US07504509-20090317-C00146.png)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019068233 2019-03-29
PCT/JP2020/014475 WO2020203950A1 (ja) 2019-03-29 2020-03-30 新規アザインドール誘導体

Publications (1)

Publication Number Publication Date
JPWO2020203950A1 true JPWO2020203950A1 (US07504509-20090317-C00146.png) 2020-10-08

Family

ID=72668977

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021512102A Pending JPWO2020203950A1 (US07504509-20090317-C00146.png) 2019-03-29 2020-03-30

Country Status (10)

Country Link
US (1) US20220162206A1 (US07504509-20090317-C00146.png)
EP (1) EP3950063A4 (US07504509-20090317-C00146.png)
JP (1) JPWO2020203950A1 (US07504509-20090317-C00146.png)
KR (1) KR20210146320A (US07504509-20090317-C00146.png)
CN (1) CN113613729A (US07504509-20090317-C00146.png)
BR (1) BR112021019050A2 (US07504509-20090317-C00146.png)
CA (1) CA3134937A1 (US07504509-20090317-C00146.png)
MX (1) MX2021011923A (US07504509-20090317-C00146.png)
SG (1) SG11202109997PA (US07504509-20090317-C00146.png)
WO (1) WO2020203950A1 (US07504509-20090317-C00146.png)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288918A (en) * 1992-09-29 1994-02-22 Union Carbide Chemicals & Plastics Technology Corporation Hydroformylation process
US5767321A (en) * 1995-12-06 1998-06-16 Union Carbide Chemicals & Plastics Technology Corporation Metal-ligand complex catalyzed processes
EP1696920B8 (en) * 2003-12-19 2015-05-06 Plexxikon Inc. Compounds and methods for development of ret modulators
JP2008503473A (ja) 2004-06-17 2008-02-07 プレキシコン,インコーポレーテッド C−kit活性を調節する化合物
WO2008063888A2 (en) * 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
EP2241333A1 (en) 2007-12-12 2010-10-20 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
KR101656548B1 (ko) 2010-03-05 2016-09-09 에프. 호프만-라 로슈 아게 인간 csf-1r에 대한 항체 및 이의 용도
US9358235B2 (en) * 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
WO2016062790A1 (en) * 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv New pyrazolopyrimidine derivatives as nik inhibitors
SG10201912699RA (en) * 2015-07-20 2020-02-27 Genzyme Corp Colony stimulating factor-1 receptor (csf-1r) inhibitors
US20200071326A1 (en) * 2017-04-14 2020-03-05 Syros Pharmaceuticals, Inc. Tam kinase inhibitors

Also Published As

Publication number Publication date
US20220162206A1 (en) 2022-05-26
EP3950063A4 (en) 2022-11-30
WO2020203950A1 (ja) 2020-10-08
CA3134937A1 (en) 2020-10-08
CN113613729A (zh) 2021-11-05
MX2021011923A (es) 2021-11-03
EP3950063A1 (en) 2022-02-09
KR20210146320A (ko) 2021-12-03
BR112021019050A2 (pt) 2021-11-30
SG11202109997PA (en) 2021-10-28

Similar Documents

Publication Publication Date Title
BR112021017339A2 (US07504509-20090317-C00146.png)
BR112021018450A2 (US07504509-20090317-C00146.png)
BR112021017939A2 (US07504509-20090317-C00146.png)
BR112021017892A2 (US07504509-20090317-C00146.png)
BR112021017782A2 (US07504509-20090317-C00146.png)
AU2020104490A5 (US07504509-20090317-C00146.png)
BR112019016138A2 (US07504509-20090317-C00146.png)
BR112021018168A2 (US07504509-20090317-C00146.png)
BR112021018452A2 (US07504509-20090317-C00146.png)
BR112021017234A2 (US07504509-20090317-C00146.png)
BR112021017355A2 (US07504509-20090317-C00146.png)
BR112021018102A2 (US07504509-20090317-C00146.png)
BR112021017173A2 (US07504509-20090317-C00146.png)
BR112021017083A2 (US07504509-20090317-C00146.png)
BR112021015080A2 (US07504509-20090317-C00146.png)
BR112021012348A2 (US07504509-20090317-C00146.png)
BR112021018250A2 (US07504509-20090317-C00146.png)
BR112021018093A2 (US07504509-20090317-C00146.png)
BR112021018084A2 (US07504509-20090317-C00146.png)
BR112021013944A2 (US07504509-20090317-C00146.png)
BR112021013128A2 (US07504509-20090317-C00146.png)
BR112021018484A2 (US07504509-20090317-C00146.png)
BR112021016821A2 (US07504509-20090317-C00146.png)
BR112021017949A2 (US07504509-20090317-C00146.png)
BR112021017983A2 (US07504509-20090317-C00146.png)